Merck's Recabrio approved by FDA for urinary and abdominal infections
Merck's Recabrio has been approved by the FDA for injection, 1.25 grams, a new combination antibacterial. Recabrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections, including pyelonephritis, caused by the susceptible Gram-negative microorganisms. Recabrio is also indicated in patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated intra-abdominal infections caused by susceptible Gram-negative microorganisms. Approval of these indications is based on limited clinical safety and efficacy data for Recabrio. Merck anticipates making Recabrio available later this year.